NAPLEX Quiz: Drug Names And Therapeutic Classes

What this quiz covers

This quiz focuses on Drug Names And Therapeutic Classes, giving you a quick way to practice the rules, question types, and explanations that matter most for NAPLEX.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

Question 1

1. Hydralazine 25 mg three times daily
2. Hydroxyzine 25 mg three times daily as needed (correct answer)
3. Losartan 100 mg daily
4. Sertraline 50 mg daily

Explanation: Drug names include generic and brand designations, while therapeutic classes categorize medications based on their mechanism of action and clinical indications. Understanding therapeutic classes is clinically relevant to identify drugs with sedative or anticholinergic effects that require patient counseling. The correct answer, hydroxyzine 25 mg three times daily as needed, represents optimal pharmacist decision-making as it is an antihistamine with significant sedation and anticholinergic risks. Hydralazine and losartan are incorrect as they are vasodilator and angiotensin II receptor blocker classes for hypertension, without sedative effects. Sertraline is also incorrect because it is a selective serotonin reuptake inhibitor for anxiety, with minimal anticholinergic activity. A clinical pearl is that first-generation antihistamines like hydroxyzine can cause drowsiness, especially in older adults. For similar mix-ups, pharmacists should counsel on class-specific side effects and monitor for uncontrolled symptoms like hypertension.

Question 2

1. Alpha-2 adrenergic agonist
2. Benzodiazepine (correct answer)
3. Selective serotonin reuptake inhibitor
4. Triptan (serotonin 5-HT1B/1D agonist)

Explanation: Drug names include generic and brand designations, while therapeutic classes categorize medications based on their mechanism of action and clinical indications. Understanding therapeutic classes is clinically relevant for distinguishing drugs with similar names but different risks, like dependence. The correct answer, benzodiazepine, represents optimal pharmacist decision-making by classifying clonazepam correctly for panic disorder counseling. Alpha-2 adrenergic agonist and selective serotonin reuptake inhibitor are incorrect as they describe clonidine and sertraline, respectively. Triptan is also incorrect because it applies to sumatriptan for migraines, not anxiolytics. A clinical pearl is that benzodiazepines like clonazepam carry risks of tolerance and withdrawal. In similar confusions, pharmacists should emphasize class-specific warnings like avoiding alcohol.

Question 3

1. Losartan 50 mg daily (angiotensin II receptor blocker) (correct answer)
2. Labetalol 100 mg twice daily (beta-blocker)
3. Nifedipine ER 30 mg daily (dihydropyridine calcium channel blocker)
4. Methyldopa 250 mg twice daily (central alpha-2 agonist)

Explanation: Drug names include generic and brand designations, while therapeutic classes categorize medications based on their mechanism of action and clinical indications. Understanding therapeutic classes is clinically relevant for identifying fetal risks in pregnant patients with hypertension. The correct answer, losartan 50 mg daily (angiotensin II receptor blocker), represents optimal pharmacist decision-making as it is contraindicated in pregnancy due to teratogenicity. Labetalol and nifedipine ER are incorrect as beta-blocker and calcium channel blocker classes, safer in pregnancy. Methyldopa is also incorrect because it is a preferred central alpha-2 agonist for gestational hypertension. A clinical pearl is that ARBs can cause oligohydramnios and renal defects in fetuses. In similar decisions, pharmacists should consult ACOG guidelines for class safety in pregnancy.

Question 4

1. Colchicine 0.6 mg tablets twice daily (correct answer)
2. Allopurinol 300 mg tablets daily
3. Indomethacin 50 mg three times daily as needed
4. Prednisone 40 mg daily for 5 days

Explanation: Drug names include generic and brand designations, while therapeutic classes categorize medications based on their mechanism of action and clinical indications. Understanding therapeutic classes is clinically relevant for guiding formulary substitutions without altering therapy efficacy in gout management. The correct answer, colchicine 0.6 mg tablets twice daily, represents optimal pharmacist decision-making as it maintains the same anti-inflammatory drug for prophylaxis. Allopurinol and indomethacin are incorrect as they are xanthine oxidase inhibitor and NSAID classes, respectively. Prednisone is also incorrect because it is a corticosteroid, not a direct substitute for colchicine. A clinical pearl is that colchicine formulations may differ in bioavailability, requiring dose verification. For similar restrictions, pharmacists should prioritize same-drug switches before class alternatives.

Question 5

1. Prednisone 40 mg daily for 5 days (correct answer)
2. Albuterol HFA 2 puffs every 4–6 hours as needed
3. Montelukast 10 mg nightly
4. Ipratropium nasal spray 2 sprays per nostril twice daily

Explanation: Drug names include generic and brand designations, while therapeutic classes categorize medications based on their mechanism of action and clinical indications. Understanding therapeutic classes is clinically relevant for distinguishing systemic from local effects in corticosteroid use. The correct answer, prednisone 40 mg daily for 5 days, represents optimal pharmacist decision-making as it identifies the systemic glucocorticoid class for asthma exacerbations. Albuterol HFA and montelukast are incorrect as beta-agonist and leukotriene inhibitor classes, respectively. Ipratropium nasal spray is also incorrect because it is an anticholinergic for rhinitis, not systemic. A clinical pearl is that systemic corticosteroids can elevate glucose in short bursts. For similar questions, pharmacists should clarify route and class to address patient concerns.

Question 6

1. Albuterol HFA 2 puffs every 4–6 hours as needed
2. Tiotropium (Spiriva) 2 inhalations once daily (correct answer)
3. Budesonide/formoterol (Symbicort) 2 inhalations twice daily
4. Fluticasone nasal spray 1 spray per nostril daily

Explanation: Drug names include generic and brand designations, while therapeutic classes categorize medications based on their mechanism of action and clinical indications. Understanding therapeutic classes is clinically relevant for differentiating inhalers and ensuring proper COPD control. The correct answer, tiotropium (Spiriva) 2 inhalations once daily, represents optimal pharmacist decision-making as it identifies the long-acting muscarinic antagonist class. Albuterol HFA and budesonide/formoterol are incorrect as short-acting beta-agonist and ICS/LABA classes, respectively. Fluticasone nasal spray is also incorrect because it is an intranasal corticosteroid for allergies. A clinical pearl is that LAMAs like tiotropium are foundational for COPD maintenance. In similar confusions, pharmacists should demonstrate device use and confirm class per GOLD guidelines.

Question 7

1. Losartan 100 mg daily
2. Lisinopril 20 mg daily (correct answer)
3. Metformin 1000 mg twice daily
4. Amlodipine 5 mg daily

Explanation: Drug names include generic and brand designations, while therapeutic classes categorize medications based on their mechanism of action and clinical indications. Understanding therapeutic classes is clinically relevant for preventing hyperkalemia and duplication in renin-angiotensin system inhibition. The correct answer, lisinopril 20 mg daily, represents optimal pharmacist decision-making by identifying it as the ACE inhibitor class. Losartan and amlodipine are incorrect as angiotensin II receptor blocker and calcium channel blocker classes, respectively. Metformin is also incorrect because it is a biguanide for diabetes, not antihypertensives. A clinical pearl is that combining ACE inhibitors and ARBs increases hyperkalemia risk in nephropathy. For similar cases, pharmacists should monitor potassium and recommend single-class therapy.

Question 8

1. Xanthine oxidase inhibitor (correct answer)
2. Benzodiazepine
3. Uricosuric agent
4. Nonsteroidal anti-inflammatory drug

Explanation: Drug names include generic and brand designations, while therapeutic classes categorize medications based on their mechanism of action and clinical indications. Understanding therapeutic classes is clinically relevant for differentiating urate-lowering from anxiolytic agents. The correct answer, xanthine oxidase inhibitor, represents optimal pharmacist decision-making by classifying allopurinol for gout. Benzodiazepine and uricosuric agent are incorrect as they describe alprazolam and probenecid, respectively. Nonsteroidal anti-inflammatory drug is also incorrect because it applies to ibuprofen, not allopurinol. A clinical pearl is that allopurinol requires HLA-B*5801 testing in high-risk populations for hypersensitivity. For similar confusions, pharmacists should counsel on class-specific monitoring like uric acid levels.

Question 9

1. Selective alpha-1 adrenergic blocker (correct answer)
2. Selective estrogen receptor modulator
3. 5-alpha-reductase inhibitor
4. Antimuscarinic for overactive bladder

Explanation: Drug names include generic and brand designations, while therapeutic classes categorize medications based on their mechanism of action and clinical indications. Understanding therapeutic classes is clinically relevant for clarifying drug purposes and avoiding mix-ups with similar names. The correct answer, selective alpha-1 adrenergic blocker, represents optimal pharmacist decision-making by classifying tamsulosin for BPH symptoms. Selective estrogen receptor modulator and 5-alpha-reductase inhibitor are incorrect as they describe tamoxifen and finasteride, respectively. Antimuscarinic is also incorrect because it applies to oxybutynin for bladder issues. A clinical pearl is that alpha-1 blockers like tamsulosin can cause orthostasis, especially with antihypertensives. For similar queries, pharmacists should differentiate classes by indication and mechanism.

Question 10

1. Propranolol 40 mg twice daily (nonselective beta-blocker) (correct answer)
2. Albuterol HFA 2 puffs every 4–6 hours as needed (short-acting beta-2 agonist)
3. Fluticasone/salmeterol 1 inhalation twice daily (ICS/LABA)
4. Primidone 50 mg nightly (barbiturate-related anticonvulsant)

Explanation: Drug names include generic and brand designations, while therapeutic classes categorize medications based on their mechanism of action and clinical indications. Understanding therapeutic classes is clinically relevant for assessing contraindications in patients with respiratory comorbidities. The correct answer, propranolol 40 mg twice daily (nonselective beta-blocker), represents optimal pharmacist decision-making as it is inappropriate in asthma due to bronchospasm risk. Albuterol HFA and fluticasone/salmeterol are incorrect as beta-2 agonist and ICS/LABA classes, beneficial for asthma. Primidone is also incorrect because it is an anticonvulsant, not directly contraindicated. A clinical pearl is that nonselective beta-blockers block beta-2 receptors, exacerbating asthma. In similar cases, pharmacists should recommend cardioselective beta-blockers like metoprolol.

Question 11

1. Intranasal corticosteroid (correct answer)
2. Oral second-generation antihistamine
3. Leukotriene receptor antagonist
4. Intranasal anticholinergic

Explanation: Recognizing drug names across different formulations and understanding therapeutic classes prevents medication errors and therapeutic duplications. Understanding that the same active ingredient can be marketed under different brand names for different routes of administration is essential for patient counseling and preventing confusion. Fluticasone intranasal (Flonase) is an intranasal corticosteroid, which represents the first-line therapy for allergic rhinitis due to its anti-inflammatory effects on nasal mucosa. The patient's confusion arose because she already purchased OTC Flonase (fluticasone) and received a prescription for the same medication, creating unnecessary duplication rather than a different therapeutic class like oral antihistamines (systemic H1 blockers), leukotriene receptor antagonists (which block inflammatory mediators), or intranasal anticholinergics (which reduce rhinorrhea through different mechanisms). A clinical pearl is that intranasal corticosteroids are more effective than oral antihistamines for nasal congestion and are the preferred initial therapy for persistent allergic rhinitis symptoms.

Question 12

1. Selective COX-2 inhibitor NSAID (correct answer)
2. Selective serotonin reuptake inhibitor
3. Opioid analgesic
4. Corticosteroid

Explanation: Drug names include generic and brand designations, while therapeutic classes categorize medications based on their mechanism of action and clinical indications. Understanding therapeutic classes is clinically relevant for separating anti-inflammatory from antidepressant drugs with similar names. The correct answer, selective COX-2 inhibitor NSAID, represents optimal pharmacist decision-making by classifying celecoxib for arthritis. Selective serotonin reuptake inhibitor and opioid analgesic are incorrect as they describe citalopram and morphine, respectively. Corticosteroid is also incorrect because it applies to prednisone, not COX-2 inhibitors. A clinical pearl is that COX-2 inhibitors like celecoxib have lower GI risk but cardiovascular concerns. For similar queries, pharmacists should highlight class differences in indications and side effects.

Question 13

1. Esomeprazole 40 mg daily (correct answer)
2. Famotidine 20 mg twice daily
3. Sucralfate 1 g four times daily
4. Calcium carbonate 1000 mg as needed

Explanation: Drug names include generic and brand designations, while therapeutic classes categorize medications based on their mechanism of action and clinical indications. Understanding therapeutic classes is clinically relevant for detecting duplication in acid-suppressive therapies for GERD. The correct answer, esomeprazole 40 mg daily, represents optimal pharmacist decision-making as it identifies the proton pump inhibitor class duplicating omeprazole. Famotidine and sucralfate are incorrect as H2-receptor antagonist and mucosal protectant classes, respectively. Calcium carbonate is also incorrect because it is an antacid, not a PPI. A clinical pearl is that long-term PPIs can lead to hypomagnesemia or bone fractures. In similar duplications, pharmacists should recommend deprescribing one agent and monitor for rebound acid.

Question 14

1. Valsartan 80 mg daily (angiotensin II receptor blocker)
2. Verapamil ER 240 mg daily (non-dihydropyridine calcium channel blocker) (correct answer)
3. Amlodipine 5 mg daily (dihydropyridine calcium channel blocker)
4. Metoprolol succinate 50 mg daily (beta-blocker)

Explanation: Drug names include generic and brand designations, while therapeutic classes categorize medications based on their mechanism of action and clinical indications. Understanding therapeutic classes is clinically relevant as it allows pharmacists to assess contraindications, potential interactions, and patient-specific risks. The correct answer, verapamil ER (non-dihydropyridine calcium channel blocker), represents optimal pharmacist decision-making by identifying it as contraindicated in heart failure with reduced ejection fraction due to its negative inotropic effects. Valsartan, an angiotensin II receptor blocker, is incorrect as it is recommended for heart failure management, and amlodipine, a dihydropyridine calcium channel blocker, is not contraindicated in this setting. Metoprolol succinate, a beta-blocker, is also incorrect because it is a standard therapy for heart failure, unlike verapamil which exacerbates symptoms. A clinical pearl is that non-dihydropyridine calcium channel blockers should be avoided in systolic heart failure to prevent worsening cardiac output. When faced with similar decisions, pharmacists should review guidelines like ACC/AHA for class-specific contraindications in comorbidities.

Question 15

1. Celecoxib 200 mg PO daily (NSAID, COX-2 selective) (correct answer)
2. Acetaminophen 650 mg PO every 6 hours as needed (analgesic/antipyretic)
3. Hydrochlorothiazide 25 mg PO daily (thiazide diuretic)
4. Lisinopril 20 mg PO daily (ACE inhibitor)

Explanation: Understanding therapeutic class contraindications based on organ function and drug interactions is essential for safe prescribing in special populations. NSAIDs, including COX-2 selective inhibitors, reduce prostaglandin synthesis, which can impair renal function and increase potassium retention, particularly when combined with ACE inhibitors. Celecoxib (COX-2 selective NSAID) is contraindicated due to the patient's advanced CKD (CrCl 24 mL/min), existing hyperkalemia (K+ 5.1 mEq/L), and concurrent ACE inhibitor use, as NSAIDs can precipitate acute kidney injury and dangerous hyperkalemia in this setting. Acetaminophen is the preferred analgesic in CKD as it doesn't affect renal function or potassium, hydrochlorothiazide may actually help lower potassium in this hyperkalemic patient, and lisinopril, while requiring monitoring in CKD, provides cardiovascular and renal protection when used carefully. A clinical pearl is that all NSAIDs, regardless of COX selectivity, should be avoided in patients with CrCl <30 mL/min, especially when combined with ACE inhibitors or ARBs due to risk of hyperkalemia and acute kidney injury.

Question 16

1. Empagliflozin 25 mg daily
2. Semaglutide 0.25 mg subcutaneously once weekly (correct answer)
3. Metformin 1000 mg twice daily
4. Insulin lispro 5 units with meals

Explanation: Drug names include generic and brand designations, while therapeutic classes categorize medications based on their mechanism of action and clinical indications. Understanding therapeutic classes is clinically relevant for educating on injectable diabetes therapies and their distinct mechanisms. The correct answer, semaglutide 0.25 mg subcutaneously once weekly, represents optimal pharmacist decision-making as it identifies the GLP-1 receptor agonist class. Empagliflozin and metformin are incorrect as SGLT2 inhibitor and biguanide classes, respectively. Insulin lispro is also incorrect because it is a rapid-acting insulin, not a GLP-1 agonist. A clinical pearl is that GLP-1 agonists promote weight loss and cardiovascular benefits in diabetes. For similar cases, pharmacists should demonstrate injection technique and differentiate classes by administration frequency.

Question 17

1. Hydroxyzine 25 mg PO three times daily as needed (first-generation antihistamine) (correct answer)
2. Hydralazine 25 mg PO three times daily (direct vasodilator)
3. Furosemide 40 mg PO daily (loop diuretic)
4. Lisinopril 10 mg PO daily (ACE inhibitor)

Explanation: Distinguishing between similar drug names and understanding their therapeutic classes prevents serious medication errors and ensures appropriate therapy. First-generation antihistamines like hydroxyzine have significant anticholinergic properties that can cause sedation, confusion, urinary retention, and increased fall risk, making them potentially inappropriate medications in older adults according to Beers Criteria. Hydroxyzine (first-generation antihistamine) requires counseling due to its sedating and anticholinergic effects, which are particularly concerning in this 71-year-old patient. Hydralazine (direct vasodilator) would be appropriate for additional blood pressure control in heart failure, furosemide (loop diuretic) is standard therapy for volume management in HF, and lisinopril (ACE inhibitor) is guideline-directed medical therapy for HFrEF. A clinical pearl is that hydroxyzine and hydralazine are commonly confused look-alike/sound-alike medications, and pharmacists should verify the indication when dispensing either medication to prevent errors.

Question 18

1. Sitagliptin 100 mg PO daily (DPP-4 inhibitor)
2. Liraglutide 1.8 mg subcutaneously once daily (GLP-1 receptor agonist) (correct answer)
3. Insulin glargine 10 units subcutaneously nightly (basal insulin)
4. Semglee (insulin glargine-yfgn) 10 units subcutaneously nightly (basal insulin biosimilar)

Explanation: Understanding therapeutic alternatives within the same drug class enables appropriate formulary substitutions while maintaining clinical benefits, particularly for medications with proven cardiovascular outcomes. GLP-1 receptor agonists stimulate insulin secretion, suppress glucagon, and slow gastric emptying, with certain agents demonstrating cardiovascular benefit in patients with established ASCVD. Liraglutide (GLP-1 receptor agonist) should be substituted for semaglutide as both are GLP-1 agonists with proven cardiovascular benefits in patients with T2DM and ASCVD, making it the appropriate formulary alternative. Sitagliptin (DPP-4 inhibitor) works through a different mechanism and lacks cardiovascular outcome benefits, insulin glargine and its biosimilar Semglee are basal insulins that would represent a change in therapeutic approach rather than a formulary substitution within the same class. A clinical pearl is that among GLP-1 agonists, liraglutide, semaglutide, and dulaglutide have demonstrated cardiovascular benefits in outcome trials, making them interchangeable for patients with T2DM and ASCVD, though dosing frequency differs.

Question 19

1. Atypical antipsychotic (dopamine/serotonin antagonist)
2. 5-HT3 receptor antagonist antiemetic (correct answer)
3. Benzodiazepine anxiolytic
4. H2 receptor antagonist

Explanation: Recognizing look-alike/sound-alike medications and understanding their different therapeutic classes prevents serious medication errors that could result in patient harm. Ondansetron and olanzapine are well-documented confused drug names that represent completely different therapeutic classes with distinct safety profiles and monitoring requirements. Ondansetron is a 5-HT3 receptor antagonist antiemetic that blocks serotonin receptors in the chemoreceptor trigger zone and is appropriate for treating nausea. The look-alike/sound-alike error with olanzapine (atypical antipsychotic) could cause serious harm as antipsychotics have significant metabolic, cardiovascular, and neurologic side effects, while benzodiazepines would cause sedation and potential respiratory depression with concurrent buprenorphine, and H2 antagonists treat acid-related disorders rather than nausea. A clinical pearl is that ondansetron can prolong QT interval, requiring caution in patients with baseline QTc prolongation or those taking other QT-prolonging medications, and maximum single dose should not exceed 16 mg due to cardiac risks.

Question 20

1. Spironolactone 50 mg PO daily (aldosterone antagonist/potassium-sparing diuretic) (correct answer)
2. Spironolactone 50 mg/5 mL oral suspension applied topically daily (topical retinoid)
3. Spiriva (tiotropium) 18 mcg inhaled once daily (LAMA bronchodilator)
4. Sertraline 50 mg PO daily (SSRI antidepressant)

Explanation: Understanding that medications can have multiple indications based on their pharmacologic properties helps explain off-label uses and ensures appropriate monitoring. Spironolactone, primarily known as a potassium-sparing diuretic for heart failure and hypertension, also has antiandrogen effects that make it useful for hormonal acne treatment in women. Spironolactone 50 mg PO daily (aldosterone antagonist/potassium-sparing diuretic) requires counseling because it can increase potassium levels and has antiandrogen effects beneficial for acne but requiring pregnancy prevention. The prescription is not for a topical formulation (oral spironolactone is used systemically for acne), not Spiriva (tiotropium, a LAMA bronchodilator with a similar sounding name), and not sertraline (an SSRI antidepressant with a somewhat similar name). A clinical pearl is that spironolactone for acne requires lower doses (25-100 mg daily) than for heart failure (up to 50 mg daily), and women of childbearing potential need effective contraception due to potential feminization of male fetuses.